Clinical Trials Directory

Trials / Completed

CompletedNCT03626896

Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) Patients

A FIH Feasibility Study to Evaluate the Safety of Transient Disruption of Blood-brain Barrier in Recurrent Glioblastoma Multiforme (GBM) Patients Using NaviFUS System

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
6 (actual)
Sponsor
NaviFUS Corporation · Industry
Sex
All
Age
20 Years
Healthy volunteers
Not accepted

Summary

This study is to evaluate the safety and find the tolerated ultrasound dose of transient opening of the blood-brain barrier (BBB) by using the NaviFUS System in recurrent GBM patients.

Detailed description

This is a feasibility, open-label, single-arm, and dose escalation study. Eligible patients will be enrolled through the process of informed consent. Patients will be assigned into different dose groups generated from the NaviFUS System to transiently open the BBB in patients with recurrent GBM who will undergo surgery within 2 weeks. The focused ultrasound (FUS) dose is selected based on the results of pre-clinical Good Laboratory Practice (GLP) safety studies as well as other non-GLP primate studies. This study will evaluate the safety and the tolerated ultrasound dose of temporary disruption of the BBB in patients with recurrent GBM. To find the tolerated ultrasound dose, the data and safety monitoring board (DSMB) will review the study data and provide the recommendations regarding continuation, termination, or other modifications of the study based on evaluation of observed adverse effects of the intervention. The extent and magnitude of BBB opening will be evaluated using of dynamic contrast-enhanced MRI (DCE-MRI).

Conditions

Interventions

TypeNameDescription
DEVICENaviFUS SystemBBB Disruption by FUS in recurrent GBM Other Name: Neuronavigation-guided focus ultrasound system

Timeline

Start date
2018-08-17
Primary completion
2019-05-20
Completion
2019-06-19
First posted
2018-08-13
Last updated
2019-06-21

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT03626896. Inclusion in this directory is not an endorsement.